Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics Inc (NQ: ELTX )

4.780 +0.620 (+14.90%)
Streaming Delayed Price Updated: 11:01 AM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elicio Therapeutics Inc

< Previous 1 2 3 Next >
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Reports Inducement Grants
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Three Upcoming Presentations Focused on its Lymph Node Targeted, mKRAS-Specific Amphiphile Vaccines
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024
ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Closing of Private Placement of $20.0 Million Convertible Note
From Elicio Therapeutics Inc.
Via GlobeNewswire
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday?
Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors. 
Via Benzinga
Elicio Therapeutics Announces Pricing of $11.5 Million Underwritten Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today?
Elicio Therapeutics stock is down on Friday after the company announced a proposed public offering for shares of ELTX this morning. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower! 
Via InvestorPlace
Elicio Therapeutics Announces Proposed Public Offering
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P
ELI-002 7P administered as a monotherapy at the Phase 2 dose shows preliminary encouraging Disease-Free Survival data in pancreatic ductal adenocarcinoma 
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors 
Via News Direct
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024
ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry 
Via News Direct
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Unlocking the Power of Immunotherapy: Elicio Therapeutics’ (NASDAQ: ELTX) Novel AMP Platform
--News Direct-- 
Via News Direct
Topics Death
Exposures Death
ELTX Stock Earnings: Elicio Therapeutics Misses EPS for Q4 2023
ELTX stock results show that Elicio Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
The 2024 Benzinga Virtual Healthcare Summit brings together top healthcare professionals and companies to discuss industry trends, advancements in technology, and the future of healthcare. Don't miss... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating Power Of Amphiphile-Immunotherapy
--News Direct-- 
Via News Direct
Elicio Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.